Radiotherapy provides local disease control for patients suffering from unresectable extrahepatic bile duct cancer, but tumor-related complications remain a major contributor to patient mortality, according to a retrospective study.
Radiotherapy Outcomes in Extrahepatic Bile Duct Cancer
Researchers examined outcomes for patients with localized, unresectable or inoperable extrahepatic bile duct cancer treated using conventionally fractionated radiotherapy. Most participants in the cohort presented with perihilar bile duct cancer. The median radiation dose delivered reached 54.0 Gy. Treatment techniques involved three-dimensional conformal radiotherapy in 55 patients and intensity-modulated radiotherapy in 19 patients. Furthermore, 57 patients received concurrent chemotherapy alongside their radiation therapy.
Median overall survival reached 18.3 months, while median progression-free survival landed at 11.5 months. Estimated freedom from local progression rates hit 86.3% at 1 year and dropped to 36.2% at 2 years.
Distant Metastasis Versus Local Complications in Treatment Failure
Distant metastasis emerged as the most common first pattern of treatment failure, impacting 52.7% of patients. Locoregional progression followed as the first failure pattern in 20.3% of cases. Despite distant spread taking the lead in recurrence patterns, local complications proved to be a critical hazard. Out of 65 patients who died during the observation window, cholangitis, liver failure, and tumor bleeding drove 26 deaths. This cluster accounts for at least 40.0% of all recorded fatalities. Study authors noted that the true proportion could be even higher because exact causes of death remained unavailable for a subset of patients.
Treatment Toxicity and Radiation Doses Above 54 Gy
The retrospective analysis identified zero cases of acute gastrointestinal toxicity of Grade 3 or higher. However, late toxicity of Grade 3 or higher developed in 8.1% of patients. When evaluating dosage efficacy, investigators discovered that radiation doses exceeding 54 Gy showed no significant association with improved freedom from local progression, progression-free survival, or overall survival.
Frequently Asked Questions About Bile Duct Cancer Radiotherapy
What caused most patient deaths despite successful local disease control?
Cholangitis, liver failure, and tumor bleeding caused at least 40.0% of all deaths among the 65 patients who died in the study.
What was the median radiation dose administered to the study cohort?
The median radiation dose delivered to patients was 54.0 Gy, utilizing either three-dimensional conformal radiotherapy or intensity-modulated radiotherapy.
How frequently did distant metastasis occur compared to locoregional progression?
Distant metastasis served as the primary pattern of treatment failure in 52.7% of patients, whereas locoregional progression acted as the first failure pattern in 20.3% of cases.
Did higher radiation doses improve survival outcomes for these patients?
Radiation doses exceeding 54 Gy showed no statistically significant association with freedom from local progression, progression-free survival, or overall survival.
Keep reading